Generic placeholder image

Coronaviruses

Editor-in-Chief

ISSN (Print): 2666-7967
ISSN (Online): 2666-7975

Perspective Article

Possible Benefits of Reformulating Antiviral Drugs with Nanoemulsion System in the Treatment of Novel Coronavirus Infection

Author(s): Manish Kumar* and Chandra Prakash Jain

Volume 2, Issue 4, 2021

Published on: 14 October, 2020

Page: [411 - 414] Pages: 4

DOI: 10.2174/2666796701999201014160116

Abstract

Background: An outbreak of SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) infection or COVID 19 has caused serious threats to all around the world. Until an effective and safe vaccine for novel coronavirus is developed by scientists, current drug therapy should be optimized for the control and treatment of COVID 19.

Objective: In this manuscript, we present a perspective on possible benefits of reformulating antiviral drug dosage form with nanoemulsion system against novel coronavirus infection.

Methods: Literature review has been done on COVID 19, treatment strategies, novel drug delivery systems and the role of pulmonary surfactant in lung protection.

Results: Nanoemulsion system and its components have certain biophysical properties which could increase the efficacy of drug therapy. Antiviral drugs, delivered through a nanoemulsion system containing P-gp inhibitor (surfactant and co-solvent), can minimize the cellular resistance to drugs and would potentiate the antiviral action of drugs. Pulmonary Surfactant (PS) assisted antiviral drug delivery by nanoemulsion system could be another effective approach for the treatment of COVID 19. The use of functional excipients like Pulmonary Surfactant (PS) and Surfactant Proteins (SPs) in the formulation of the antiviral drug-loaded nanoemulsion system can improve the treatment of coronavirus infection.

Conclusion: In our opinion, for synergizing antiviral action, lipid and protein portion of PS and their commercial analogs should be explored by pharmaceutical scientists to use them as a functional excipient in the formulation of antiviral drug-loaded nanoemulsion system.

Keywords: Antiviral drugs, COVID 19, nanoemulsion, nanotechnology, reformulation, pulmonary surfactant (PS).

[1]
Sohrabi C, Alsafi Z, O’Neill N, et al. World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19). Int J Surg 2020; 76: 71-6.
[http://dx.doi.org/10.1016/j.ijsu.2020.02.034] [PMID: 32112977]
[2]
Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents 2020; 55(3)105924
[http://dx.doi.org/10.1016/j.ijantimicag.2020.105924] [PMID: 32081636]
[3]
Bhavana V, Thakor P, Singh SB, Mehra NK. COVID-19: Pathophysiology, treatment options, nanotechnology approaches, and research agenda to combating the SARS-CoV2 pandemic. Life Sci 2020; 261118336
[http://dx.doi.org/10.1016/j.lfs.2020.118336]]
[4]
Kumar M, Bishnoi RS, Shukla AK, Jain CP. Techniques for formulation of nanoemulsion drug delivery system: A review. Prev Nutr Food Sci 2019; 24(3): 225-34.
[http://dx.doi.org/10.3746/pnf.2019.24.3.225] [PMID: 31608247]
[5]
Qadir A, Faiyazuddin MD, Talib Hussain MD, Alshammari TM, Shakeel F. Critical steps and energetics involved in a successful development of a stable nanoemulsion. J Mol Liq 2016; 214: 7-18.
[http://dx.doi.org/10.1016/j.molliq.2015.11.050]
[6]
Cojocaru FD, Botezat D, Gardikiotis I, et al. Nanomaterials designed for antiviral drug delivery transport across biological barriers. Pharmaceutics 2020; 12(2): 1-34.
[http://dx.doi.org/10.3390/pharmaceutics12020171] [PMID: 32085535]
[7]
Shah K, Chan LW, Wong TW. Critical physicochemical and biological attributes of nanoemulsions for pulmonary delivery of rifampicin by nebulization technique in tuberculosis treatment. Drug Deliv 2017; 24(1): 1631-47.
[http://dx.doi.org/10.1080/10717544.2017.1384298] [PMID: 29063794]
[8]
Chuesiang P, Siripatrawan U, Sanguandeekul R, McLandsborough L, Julian McClements D. Optimization of cinnamon oil nanoemulsions using phase inversion temperature method: Impact of oil phase composition and surfactant concentration. J Colloid Interface Sci 2018; 514: 208-16.
[http://dx.doi.org/10.1016/j.jcis.2017.11.084] [PMID: 29257975]
[9]
Orhan I, Ozcelik B, Sener B. Evaluation of antibacterial, antifungal, antiviral, and antioxidant potentials of some edible oils and their fatty acid profiles. Turk J Biol 2011; 35(2): 251-8.
[10]
Brochot A, Guilbot A, Haddioui L, Roques C. Antibacterial, antifungal, and antiviral effects of three essential oil blends. MicrobiologyOpen 2017; 6(4): 1-6.
[http://dx.doi.org/10.1002/mbo3.459] [PMID: 28296357]
[11]
Chatterjee B, Hamed Almurisi S, Ahmed Mahdi Dukhan A, Mandal UK, Sengupta P. Controversies with self-emulsifying drug delivery system from pharmacokinetic point of view. Drug Deliv 2016; 23(9): 3639-52.
[http://dx.doi.org/10.1080/10717544.2016.1214990] [PMID: 27685505]
[12]
Shinde RL, Jindal AB, Devarajan PV. Microemulsions and nanoemulsions for targeted drug delivery to the brain. Curr Nanosci 2011; 7(1): 119-33.
[http://dx.doi.org/10.2174/157341311794480282]
[13]
Raghava KM, Lakshmi PK. Overview of P-glycoprotein inhibitors: A rational outlook. Braz J Pharm Sci 2012; 48(3): 353-67.
[http://dx.doi.org/10.1590/S1984-82502012000300002]
[14]
Turriziani O, Antonelli G, Dianzani F. Cellular factors involved in the induction of resistance of HIV to antiretroviral agents. Int J Antimicrob Agents 2000; 16(3): 353-6.
[http://dx.doi.org/10.1016/S0924-8579(00)00264-8] [PMID: 11091062]
[15]
Parra E, Pérez-Gil J. Composition, structure and mechanical properties define performance of pulmonary surfactant membranes and films. Chem Phys Lipids 2015; 185: 153-75.
[http://dx.doi.org/10.1016/j.chemphyslip.2014.09.002] [PMID: 25260665]
[16]
Pilcer G, Amighi K. Formulation strategy and use of excipients in pulmonary drug delivery. Int J Pharm 2010; 392(1-2): 1-19.
[http://dx.doi.org/10.1016/j.ijpharm.2010.03.017] [PMID: 20223286]
[17]
Guagliardo R, Pérez-Gil J, De Smedt S, Raemdonck K. Pulmonary surfactant and drug delivery: focusing on the role of surfactant proteins. J Control Release 2018; 291: 116-26.
[http://dx.doi.org/10.1016/j.jconrel.2018.10.012] [PMID: 30321577]
[18]
Hartshorn KL. Role of surfactant protein A and D (SP-A and SP-D) in human antiviral host defense. Front Biosci - Sch 2010; 2(2): 527-46.
[19]
Leth-Larsen R, Zhong F, Chow VTK, Holmskov U, Lu J. The SARS coronavirus spike glycoprotein is selectively recognized by lung surfactant protein D and activates macrophages. Immunobiology 2007; 212(3): 201-11.
[http://dx.doi.org/10.1016/j.imbio.2006.12.001] [PMID: 17412287]
[20]
Wilde P, Mackie A, Husband F, Gunning P, Morris V. Proteins and emulsifiers at liquid interfaces. Adv Colloid Interface Sci 2004; 108-109: 63-71.
[http://dx.doi.org/10.1016/j.cis.2003.10.011]
[21]
Li Y, Jin H, Sun X, et al. Physicochemical properties and storage stability of food protein-stabilized nanoemulsions. Nanomaterials (Basel) 2018; 9(1): 1-14.
[http://dx.doi.org/10.3390/nano9010025] [PMID: 30585224]

© 2022 Bentham Science Publishers | Privacy Policy